Last update: Dec. 8, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
An Fc-peptide fusion protein that acts as an agonist in the thrombopoietin receptor stimulating platelet production.
Indicated in the treatment of chronic immune thrombocytopenic purpura (ITP) when resistant to other treatments (corticoids, immunoglobulins).
Administered subcutaneously once a week.
Since the last update, we have not found published data on its excretion in breast milk.
Its very high molecular weight makes it very unlikely that it will transfer to milk in significant quantities.
Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so that its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.
We do not have alternatives for Romiplostim.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.